RxDoctor Payments Data

Mehmood Rashid, MD

Neurology · Toledo, OHNPI 1275833980

Payments from drug & device makers

$3,114in general payments, 2019–2025

Across 70 payments — averaging $44.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • AbbVie$615
  • Teva Pharmaceuticals USA, Inc.$374
  • Medtronic$232
  • Revance Therapeutics, Inc.$192
  • Amneal Pharmaceuticals LLC$95
  • plus $246 from 10 others

What the payments were for

  • Travel & lodging$99332%
  • Food & beverage$1,78757%
  • Education$33411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,114 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$50,348
Medicare patients
244
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate58$441,528
AustedoDeutetrabenazine11$106,271
RytaryCarbidopa/Levodopa59$91,378
GocovriAmantadine Hcl20$64,727
Droxidopa12$64,088
NuplazidPimavanserin Tartrate12$63,044
Carbidopa-Levodopa ErCarbidopa/Levodopa297$25,623
Rasagiline Mesylate64$14,991
Carbidopa-LevodopaCarbidopa/Levodopa332$11,921
Rivastigmine41$11,330
Pramipexole ErPramipexole Di-Hcl11$8,374
Ropinirole ErRopinirole Hcl27$6,138
Gabapentin196$5,301
Primidone106$3,866
AmantadineAmantadine Hcl45$2,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$374$106,27111 claims
Amneal Pharmaceuticals LLCRytary$95$91,37859 claims
Acadia Pharmaceuticals IncNuplazid$13$63,04412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.

Other neurology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →